Merck KGaA of Germany has decided to discontinue the clinical development of the immunotherapy tecemotide in non-small cell lung cancer following the failure of a Japanese study to show effectiveness on any trial endpoint. ---Subscribe to MedNous to access this article--- Company News Clinical Research
